Stock in Focus: Flexion Therapeutics, Inc. (FLXN)
-- Sunday, February 23, 2020, 17:45 --
Company Profile: |
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts. |
Recent News: |
On Feb. 07, 2020, the company announced equity inducement grants to 13 new employees consisting of an aggregate of 40,500 stock options and 6,850 restricted stock units. |
|
Fundamental Analysis: |
Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency. |
Growth – Measures the growth of both the company’s income statement and cash flow. @@@@@ |
Profitability – Measures the historical price movement of the stock. @@@@@ |
Solvency – Measures the solvency of the company based on several ratios. @@@@@ |
Efficiency – Measures the strength and historic growth of a company’s return on invested capital. @@@@@ |
Conclusion: |
FLXN’s strengths can be seen in its better growth, strong profitability and better efficiency compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, the MACD is trying to cross back up and the RSI stands at 61.18 with positive bias. We rate Flexion Therapeutics, Inc. (FLXN) a STRONG BUY. |